Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection (960025)
Helicobacter pylori is a bacteria that infects the lining of the stomach and is associated with ulcers. Helicobacter pylori may also increase the long-term risk of developing certain forms of gastric cancer. Curing this infection generally requires that patients take 2 or more antibiotic medications and a stomach acid suppressing medication for about two weeks. Current treatments do not always cure the infection and a new treatment is being tested in this study. The drugs involved in the new 4 drug treatment have been widely used for treatment of this infection. It remains unknown what is the best and most cost effective way to give them. This study will compare three different ways of using these drugs.
Subjects must have active Helicobacter pylori infection in order to participate in this study.
|Helicobacter Infection||Drug: 10-day sequential treatment Drug: 10-day concomitant therapy||Phase 4|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
|Official Title:||Sequential Versus Concomitant Therapy for Helicobacter Pylori Infection|
- Number of Participants in Which H. Pylori Was Eradicated [ Time Frame: one month after finishing study drugs ]Evaluate eradication outcome by endoscopy urease test and histology or urea breath test
- Number of Participants Who Had Good Drug Compliance [ Time Frame: one month after finishing test therapy ]Good drug compliance is defined as taking equal to or more than 80% of eradication medicines
|Study Start Date:||May 2007|
|Study Completion Date:||June 2010|
|Primary Completion Date:||June 2010 (Final data collection date for primary outcome measure)|
Active Comparator: 10-day concomitant therapy
esomeprazole and amoxicillin and clarithromycin and metronidazole for 10 days
Drug: 10-day concomitant therapy
esomeprazole (40 mg, bid) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 10, clarithromycin (500 mg, bid) from day 1 to day 10, metronidazole (500 mg, bid) from day 1 to day 10
Other Name: Nexium-based quadruple therapy
Experimental: 10-day sequential therapy
esomeprazole and amoxicillin for 5 days, followed by esoprazole and clarithromycin and metronidazole for 5 more days
Drug: 10-day sequential treatment
esomeprazole (40 mg daily) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 5, clarithromycin (500 mg, bid) from day 6 to day 10, metronidazole (500 mg, bid) from day 6 to day 10
Other Name: Nexium-based sequential therapy
The purpose of this study is to compare different methods of giving combination drug therapy for treating Helicobacter pylori infection of the stomach. The entire study will last less than 2 years. Each subject will be participating in the study for approximately 60 days.
A total of 360 subjects will be asked to participate in this study.
Before participating in this study, subject's must have undergone to confirm the presence and to assess the susceptibility of Helicobacter pylori. Qualified subjects will receive 4 drugs which are to be taken as part of the study treatment: an acid suppressing drug (name), amoxicillin, clarithromycin and metronidazole. The doses are 1 grams of amoxicillin, 40 mg of esomeprazole (Nexium), 500 mg of metronidazole and 250 mg of clarithromycin. Each drug will be given twice a day to be taken twice a day with the morning and evening meals. Subjects will receive one of three different combinations. The choice of which will be randomly chosen by the use of a computer program. The regimes are: all 4 drugs daily for 5 days, all 4 drugs daily for 10 days, and two drugs (esomeprazole and amoxicillin) for 5 days then all for drugs for 5 additional days.
Subjects will be asked to return within 4 days after completion of the treatment to evaluate how they did with the drugs. They will be asked bring back all unused medication and the bottles or containers that the medicine was packaged in. Your medication use and tolerance to the study drugs will be assessed. The treatment portion of the study will be complete at this point.
Evaluation of the effect of the treatment will take place 4-6 weeks after the end of therapy. Subjects will come back to the study site and will have a UBT or repeat endoscopy, if clinically indicated to verify that the Helicobacter pylori has been cured. Subjects will be asked not to take antibiotics or any other drugs that may affect the outcome of the breath test used to confirm that the treatment was successful.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00656968
|Kaohsiung, Taiwan, 807|
|Kaohsiung Veterans General Hospital|
|Kaohsiung, Taiwan, 813|
|Study Chair:||Ching-Kuan Liu, MD, PhD||Kaohsiung Medical Univestity|
|Study Chair:||David Y Graham, MD||Baylor College of Medicine|
|Study Director:||Antone R Opekun, PA-C||Baylor College of Medicine|
|Principal Investigator:||Deng-Chyang Wu, MD PhD||Kaohsiung Medical University|